Regulation of Gene Expression by PI3K in Mouse Growth Plate Chondrocytes by Ulici, Veronica et al.
Regulation of Gene Expression by PI3K in Mouse Growth
Plate Chondrocytes
Veronica Ulici, Claudine G. James, Katie D. Hoenselaar, Frank Beier*
CIHR Group in Skeletal Development and Remodeling, Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada
Abstract
Background: Endochondral ossification, the process through which long bones are formed, involves chondrocyte
proliferation and hypertrophic differentiation in the cartilage growth plate. In a previous publication we showed that
pharmacological inhibition of the PI3K signaling pathway results in reduced endochondral bone growth, and in particular,
shortening of the hypertrophic zone in a tibia organ culture system. In this current study we aimed to investigate targets of
the PI3K signaling pathway in hypertrophic chondrocytes.
Methodology/Principal Findings: Through the intersection of two different microarray analyses methods (classical single
gene analysis and GSEA) and two different chondrocyte differentiation systems (primary chondrocytes treated with a
pharmacological inhibitor of PI3K and microdissected growth plates), we were able to identify a high number of genes
grouped in GSEA functional categories regulated by the PI3K signaling pathway. Genes such as Phlda2 and F13a1 were
down-regulated upon PI3K inhibition and showed increased expression in the hypertrophic zone compared to the
proliferative/resting zone of the growth plate. In contrast, other genes including Nr4a1 and Adamts5 were up-regulated
upon PI3K inhibition and showed reduced expression in the hypertrophic zone. Regulation of these genes by PI3K signaling
was confirmed by quantitative RT-PCR. We focused on F13a1 as an interesting target because of its known role in
chondrocyte hypertrophy and osteoarthritis. Mouse E15.5 tibiae cultured with LY294002 (PI3K inhibitor) for 6 days showed
decreased expression of factor XIIIa in the hypertrophic zone compared to control cultures.
Conclusions/Significance: Discovering targets of signaling pathways in hypertrophic chondrocytes could lead to targeted
therapy in osteoarthritis and a better understanding of the cartilage environment for tissue engineering.
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Introduction
PI3Ks phosphorylate the 39-OH position of the inositol ring of
inositol phospholipids, producing three lipid products: PtdIns(3)P,
PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3). These lipids bind to the
pleckstrin homology (PH) domains of proteins such as PKB (Akt)
and control the activity and subcellular localisation of a diverse
array of signal transduction molecules [1]. Akt is a serine-
threonine kinase and is one of the main targets positively regulated
by PI3K. It transduces signals from numerous extracellular stimuli
and controls processes such as glucose metabolism, cell cycle
progression, gene expression, protein synthesis and cell survival in
a wide variety of cell and tissue systems [2,3]. While several
transcription factors are known to be regulated by Akt, including
AP-1, glucocorticoid receptor and E2F [3], our knowledge of the
actual genes controlled by this pathway is relatively limited. Some
of the reported Akt-regulated genes are GLUT-1, PEPCK, VEGF,
Bcl-2 and p27 [3–10].
The PI3K/Akt pathway is generally associated with tissue
growth. We have shown earlier that inhibition of PI3K signaling
results in reduced growth of tibiae [11]. Long bones, such as tibia,
grow and elongate through the process of endochondral
ossification where skeletal elements are first laid down as cartilage
precursors and then this cartilage is replaced by bone [12,13].
During endochondral bone development, the cartilage template is
organized in 4 chondrocyte subpopulations: resting (closest to the
articular end of the bone), proliferative (the next zone towards the
middle of the bone) (which express type II collagen, Sox family
members 5,6,9, etc.), prehypertrophic and hypertrophic (the zones
closer to the mineralized area, which is located in the middle of the
bone) (expressing collagen X, Mmp13, VEGF etc) [14,15].
Hypertrophic chondrocytes are localized between proliferating
cartilage and bone and form an essential functional interface by
facilitating the transition from cartilage to bone and coupling
chondrogenesis to osteogenesis and angiogenesis [16]. Hypertro-
phic chondrocytes express and secrete numerous factors that
contribute to this coupling process such as Bone morphogenetic
proteins (BMPs), Wnts, and Ihh, all of which are important for
osteogenesis, as well as RANKL and VEGF, which promote
osteoclast activation and vascular invasion [16,17].
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endochondral ossification, but it also seems to be a pathological
event in early osteoarthritis. For example, it was shown that
formation of very early age-related OA-like lesions in the knee is
accompanied by expression of chondrocyte differentiation-related
genes associated with hypertrophy [18–20].
In a previous publication [11] we showed that Akt is activated in
the prehypertrophic/hypertrophic zone of the growth plate and
that PI3K inhibition reduces hypertrophic differentiation and
longitudinal bone growth. In the current study, we aim to identify
the target genes of the PI3K/ Akt pathway in differentiated
chondrocytes.
Methods
Ethics Statement
All animal studies were approved by the Animal Use
Subcommittee of the Council of Animal Care at the University
at Western Ontario.
Materials
Chemical reagents were purchased from Sigma, unless stated
otherwise. Timed pregnant CD1 mice were purchased from Charles
River Laboratories. Cell culture and organ culture medium
components and general chemicals were purchased from Sigma
and Invitrogen. LY294002 was purchased from Calbiochem.
Antibodies were purchased from Abcam (Factor XIIIa- # ab1834
(AC-1A1)), Sigma (anti b-actin clone AC-15) and Santa Cruz
(Phlda2 (TSSC3 (E-14) - # sc-66298), HRP conjugated goat anti-
mouse - # sc-2005, HRP conjugated donkey anti-goat - # sc-2020)
(HRP conjugated goat anti-mouse - # sc-2005). AEC substrate-
chromogen was purchased from Dako and cocktail protease and
phosphatase solutions for protein harvest from Roche (protease
inhibitor cocktail tablets –complete mini- # 836153001), Sigma
(phosphatase inhibitor cocktail 2 # P5726-5 ml) and Calbiochem
(phosphatase inhibitor cocktail IV # 524628). 10% NuPAGEHBis-
Tris Pre-Cast Gel System from Invitrogen was also used.
Primary Chondrocyte Culture
E15.5 mouse long bones were dissected, enzymatically digested
and the obtained chondrocytes were plated in 6-well NUNC plates
at a density of 2.5610
5 cells per ml in monolayer and incubated
overnight as described [21]. The following day the cells were
incubated with fresh medium containing either 10 mM LY294002
or DMSO (equal volume) for an additional 24 hours.
Organ Culture and Immunohistochemistry
Tibiae were isolated from E15.5 mice and cultured for 6 days in
serum-free medium containing either DMSO control or
LY294002 inhibitor (10 mM), as described [11]. Medium and
treatments were changed every second day. Immunohistochem-
istry protocols were performed as described [11]. Sections were
incubated in 3% H2O2 for 15 min at room temperature, followed
by incubation in preheated (2 min at 100uC) 10 mM sodium
citrate solution (pH 6.0) for 30 min at 97uC. They were then
blocked with 5% goat serum. Sections were incubated with
0.10 mg/ml factor XIIIa primary antibody over night at 4uC. The
UltraVision LP Large Volume Detection System AP Polymer was
used to recognize the primary antibody according to manufactur-
er’s instructions. After washing, the HRP (horseradish peroxidase)
conjugated polymer complex was visualized by incubation for
,5 min with AEC (3-amino-9-ethylcarbazole) substrate-chromo-
gen; sections were then counterstained with hematoxylin for
30 seconds, washed and mounted. All images were taken at room
temperature with a Retiga EX camera connected to a Leica
DMRA2 microscope. Primary image analyses were performed
using Openlab 4.0.4 and Photoshop software.
Protein Extraction
Protein samples were harvested both from primary monolayer
chondrocytes and from tibial explants. After 24 hours of primary
chondrocyte culture, the medium was replaced with ice-cold PBS;
cells were harvested and then centrifuged for 5 min at 4uC and
1000 X g. The supernatant was removed and samples were
resuspended in ice-cold RIPA lysis buffer containing protease and
phosphatase cocktails and stored at 280uC or immediately used
for western blotting [22].
Protein samples were also isolated directly from tibial explants
after 6 days of incubation with DMSO or 10 mM LY294002. Six
bones were combined from each treatment to obtain better protein
yield. The explants were washed with PBS and then weighed in
order to add a proportional amount of RIPA/cocktail buffer (1 ml
of buffer for 3 g of tissue). The tissue samples were then flash-
frozen and stored at 280uC; they were homogenized and
sonicated before protein quantification with Bicinchoninic Acid
(BCA) assay.
Western Blotting
Western blotting was performed as described [22] with minor
modifications. 20–30 mg of proteins were loaded and size-
fractioned on a 10% NuPAGEHBis-Tris Pre-Cast Gel System,
followed by gel transfer to a nitrocellulose membrane, using the
Invitrogen I-blot system. The membrane was blocked in 5% BSA-
TBST buffer for 1 hour and then incubated with primary antibody
against factor XIIIa, over-night at 4uC. The membrane was
washed in TBST and incubated with 1:3000 goat anti-mouse IgG
–HRP conjugated secondary antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Signals were visualized using the enhanced
chemiluminescence Advance Western blot detection system
(Amersham Biosciences, Piscataway, NJ) and Alphaimager 2200.
Microarray Analysis of Primary Chondrocytes
All data is MIAME compliant and the raw data has been
deposited in a MIAME compliant database (GEO). Microarray
analysis was performed as described [21–23]. Total RNA was
extracted from cultures treated with DMSO (control) or 10 mM
LY294002 for 24 hours, in 3 independent experiments. The
variability between trials was minimal (Figure S1). RNA quality
and quantity was assessed using the Agilent 2000 Bioanalyzer
system and subsequently hybridized to MOE 430 2.0 mouse chips
from Affymetrix, as previously described [21,22]. Bioanalyses,
microarray hybridization, scanning and M.A.S. 5.0 normalization
were completed at the London Regional Genomics Facility. Data
were deposited in the GEO database (NCBI Accession number:
Series GSE8488 for the inhibitor microarray data normalized with
GC_RMA algorithm to be used in GSEA analysis; NCBI
Accession number: Series GSE15069 for the inhibitor microarray
data normalized using the M.A.S 5.0. algorithm for single gene
analysis). Following the initial normalization, data was filtered
based on reliable signal using the SG1a-1 script (Signal intensity
filter) from GeneSpring GX 7.3.1. The default settings were
applied: lowest threshold-signal detection intensity =50; percent-
age of conditions in which a signal has to be higher than threshold
in order to pass =25%, where the experimental condition is
represented by samples (replicates) grouped together based on
their parameter values (e.g. DMSO treatment condition vs.
LY294002 treatment condition). As a result of this analyses, the
fold changes reported for different genes in the following results
PI3K in Chondrocytes
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was also normalized using the GC-RMA algorithm in order to
perform GSEA analysis [21].
Microarray Analysis of Microdissected Growth Plate
Microarray analysis was performed as described [21,22]. Total
RNA was extracted from microdissected growth plates from E15.5
mouse tibiae, as described [24], in 3 independent experiments.
The growth plates were manually separated into 3 main zones:
Proliferative/Resting (Zone I), Hypertrophic (Zone II) and
Mineralized (Zone III). RNA extracted separately from each zone
was then hybridized to MOE 430 2.0 mouse chips from
Affymetrix, as described above. Data normalization was
performed using the GC-RMA algorithm [21]. Data were
deposited in the GEO database (NCBI Accession number: Series
GSE7685). Data filtering was performed as described above.
RNA Isolation and Real-Time RT PCR
RNA was isolated from primary chondrocytes in monolayer
culture after 24-hour incubation with DMSO or 10 mM
LY294002, as previously described [21,22]. Taqman real-time
PCR was performed as described [22,25,26] with primers and
probe sets from Applied Biosystems. Amplified transcripts were
quantified using the standard curve method. Data were normal-
ized to Gapdh (Glyceraldehyde 3-phosphate dehydrogenase)
mRNA levels and represent averages and SE from direct
comparison of LY294002 and DMSO treatments from at least 4
different trials, determined by GraphPad Prism 4 software. The
results are presented as fold change between DMSO and
LY294002 treatments, using DMSO from each trial as reference.
A 2 sample unequal variance t-test was used –with a *p-value ,
0.05 considered significant. The expression of Phlda2 was also
analyzed by real-time PCR using RNA isolated from the 3 growth
plate zones. In this case, One-way analysis of variance with the
Newman-Keuls Multiple Comparison Test was used and a *p-
value ,0.05 was considered significant.
FatiGO Analysis
Gene lists identified by single gene microarray analysis were
compared using the FatiGO web application from BABELO-
MICS v3.1 ([27,28], http://www.babelomics.org). FatiGO asso-
ciates Gene Ontology (GO) terms (functional categories) to a
group of genes with respect to a gene set of reference [27]. The
Biological Process at level 6 was selected for functional annotations
based on the relevance of GO terms at this level for our analyses.
Functional categories were organized based on their adjusted p-
value, corrected for multiple testing.
GSEA Analysis
In addition to the single gene analyses, we used Gene Set
Enrichment Analysis (GSEA) algorithm, which is a microarray
data analysis method that uses predefined gene sets to identify
significant biological changes in microarray data sets [21]. GSEA
is especially useful when the gene expression changes in a given
microarray data set are relatively small [29,30].
In order to implement the GSEA algorithm, data was
normalized by Robust Multichip Analysis using RMAEXPRESS
software v.0.4.1 developed by B. Bolstad, University of California,
Berkeley as previously described [31]. Logarithmically trans-
formed expression values were used to implement GSEA. The
GSEA algorithm was implemented with GSEA v2.0 software
[30,32]. Ranked expression lists were derived from RMAEX-
PRESS and GeneSpring GXH 7.3.1.
Using an a priori defined set of genes (e.g. the C2 and User-
defined (UD) gene sets), the aim of GSEA is to determine if the
members of these gene sets are randomly distributed throughout
the analyzed gene list (e.g. 1.4-fold changes between DMSO and
LY294002) or mostly found at the top or bottom of the list. An
enrichment score (ES) was calculated for each of these gene sets
and it reflects the degree to which a gene set is overrepresented at
the extremes (top or bottom) of the entire gene list [30]. ES was
normalized for each gene set to account for differences in gene set
size, yielding a normalized enrichment score (NES). The false
discovery rate (FDR) corresponding to each NES was then
calculated [30]. For further analyses we used the gene sets meeting
these cut-off requirements: false discovery rate (FDR) ,25% and
p-value ,0.05. Enriched gene sets were identified in both
LY294002 and vehicle (DMSO) data. If a high number of
functional categories had FDR above 25% cut-off, then the top 20
gene sets were selected for further analysis.
User Defined (UD) Gene Sets
UD Gene sets were generated by us using the probe set search
tool and the molecular function class of Gene Ontology annotations
from GeneSpring GX 7.3.1., as described [21]. Probe set
redundancy was eliminated in all gene sets using the CollapseDa-
taset function in GSEA. All probe set identifiers were converted to
the Human Genome Organization (HUGO) annotations, and
probe sets lacking corresponding HUGO annotations were
excluded. A total of 90 user-defined gene sets were generated.
Gene Sets from the Molecular Signature Database
To provide an additional set of functional categories, we used
GSEA in combination with C2 gene sets from the GSEA
Molecular Signature Database (MgSigDB), as described (James et
al, PLoSONE, accepted December 15
th, 2009). The C2 data base
is represented by a collection of gene sets containing information
about specific biological processes, metabolic and signaling
pathways, chemical and genetic perturbations, disease phenotype
and animal models and also gene sets from the biomedical
literature. At the time of the analyses, C2 was comprised of 1137
gene sets. The gene sets from the C2 data base are separated in 2
categories: CP canonical pathways- canonical representations of
biological processes compiled by domain experts) and CGP
(chemical and genetic perturbations- gene set representing genes
induced or repressed by the perturbation) (http://www.broad.mit.
edu/gsea/msigdb/collections.jsp#C2).
Results
Genes Differentially Regulated between DMSO and
LY294002 Treatments
We performed microarray analyses to identify genes regulated
by the PI3K/Akt pathway in primary chondrocytes. We first
filtered the gene list generated with Gene Spring GX 7.3.1 based
on fold change between the DMSO and LY294002 treatments.
The starting gene list for the fold change filter was represented by
probe sets showing a reliable signal. A number of 5035 probe sets
was changed at least 1.4-fold between the 2 conditions (DMSO
and LY294002). 2703 probe sets were at least 1.4-fold up-
regulated under PI3K inhibition with LY294002 while 2332 genes
were at least 1.4-fold down-regulated by LY294002. Progressively,
416, 9 and 1 genes were 2-, 5- and 7-fold up-regulated by
LY294002, respectively, and 596, 14, 1 genes were 2-, 5-, 7-fold
down-regulated by LY294002 (Table 1). Overall the gene
expression changes were modest under PI3K inhibition with most
of the differentially expressed genes being located in the , 2-fold
PI3K in Chondrocytes
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as other authors noticed similar patterns in previous publications
[3,7]. This is one of the reasons we used the 1.4-fold change cut-
off, in addition to previous observations from our published
microarray data, showing that numerous markers of chondrocyte
differentiation and targets of our studied signaling pathways had
less than 1.5-fold change in gene expression between experimental
conditions [21].
Intersection between Genes Up-Regulated in Zone II and
Down-Regulated by LY294002 (List #1)
The main focus of this study was to identify targets of the PI3K
pathway in chondrocyte differentiation. Therefore we intersected
the genes at least 1.4-fold up-regulated in zone II (hypertrophic
zone) compared to zone I (proliferative/resting zone) (James et al,
PLoSONE, accepted December 15
th, 2009.) with the genes at least
1.4-fold down-regulated by LY294002, as potential genes up-
regulated by PI3K signaling under physiological conditions. As
before, the initial gene set for this experiment was a gene list
filtered on the reliable signal. This resulted in the identification of
371 shared genes: both up-regulated during the chondrocyte
hypertrophy and down-regulated upon PI3K inhibition (Figure 1B;
Figure 2 - #1). Considering that filtering the gene lists on both
statistical significance and reliable signal might be too stringent for
all the intersections, we decided to use only the reliable signal as
the filter for the intersected gene lists.
Intersection between Genes 1.4-Fold Up-Regulated in
Zone II and 1.4-Fold Up-Regulated by LY294002 (List #2)
The probe sets up-regulated in Zone II were also compared to
the genes up-regulated by LY294002. 297 probe sets were both
1.4-fold up-regulated in zone II and 1.4-fold up-regulated in the
LY294002 treatment (Figure 2 - #2). These genes were both up-
regulated in differentiated chondrocytes and up-regulated upon
PI3K inhibition with LY294002, opposite to the genes from the
previous results section that were down-regulated by LY294002.
Therefore, these genes appear to be down-regulated by PI3K
during chondrocyte hypertrophy.
FatiGO Functional Enrichment Identified Metabolic
Categories Associated with List #1
We compared the genes from List #1 and List #2 in order to
observe which class of genes up-regulated in zone II were down- or
up-regulated by LY294002. The previous results have shown that
a considerable number of probe sets (297) were up-regulated by
LY294002 during chondrocyte differentiation; therefore not all
probe sets associated with hypertrophy are also down-regulated by
LY294002. We wanted to investigate in more detail which specific
biological categories associated with chondrocyte differentiation
were also down-regulated by PI3K inhibition.
We observed that a number of metabolic processes from GO
Biological Process analysis was associated with List #1. Here we
only present the most significant five Biological processes. The first
two categories identified by GO biological process at level 6 are
Table 1. Number of genes differentially regulated between
DMSO and LY294002 treatments.
Fold
change
DMSO vs.
LY294002 (Total)
DMSO.
LY294002
LY294002.
DMSO
1.4 5035 2332 2703
2 1012 596 416
52 3 1 49
72 1 1
10 0 0 0
doi:10.1371/journal.pone.0008866.t001
Figure 1. Intersection between genes differentially regulated
in DMSO and LY294002 treatments and genes differentially
expressed between zone II and zone I. (A) Schematic of the growth
plate dissection used for the microdissected growth plate microarray
analysis. (B) Intersection between genes up-regulated in zone II and
down-regulated in LY294002 Genes 1.4 fold up-regulated in Zone II
compared to Zone I (James et al, in revision) were intersected with
genes 1.4 fold down-regulated by LY294002. 371 shared genes were
identified. (C) Intersection between genes down-regulated in zone II
and up-regulated in LY294002.Gene lists up-regulated by LY294002
were intersected with gene lists down-regulated in zone II. 912 probe
sets were common to both categories. (D) Expression pattern of
selected genes through out the growth plate. Adamts5 and Nr4a1 are
both decreased in zone II compared to I and III. Phlda2 is highly
increased in zone II compared to I and III. F13a1 shows increased levels
of expression from zone I to zone III.
doi:10.1371/journal.pone.0008866.g001
PI3K in Chondrocytes
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process’’ (Figure 2). 9.27% of the genes in List #1 are represented
in the ‘‘steroid metabolic process’’ and 11.22% in the ‘‘lipid
biosynthetic process’’. The ‘‘Translation’’ category was also highly
associated with List #1 (8.78% of the genes in List #1).
Intersection between Genes Down-Regulated in Zone II
and Up-Regulated by LY294002
Similar to the previous analysis, gene lists up-regulated by
LY294002 were intersected with gene lists down-regulated in zone
II, as potential gene targets down-regulated by PI3K activity under
normal conditions and with a role in earlier stages of chondrocyte
differentiation. 912 probe sets were common to both categories
(Figure 1C).
Gene Set Categories from C2 and UD Databases Enriched
in DMSO or LY294002 Conditions
As described in the Methods section, in addition to the single
gene analyses we used the GSEA algorithm, which is a
microarray data analysis method that uses predefined gene sets
and ranks of genes to identify significant biological changes in
microarray data sets [21]. After performing the GSEA
algorithm in association with the UD and C2 data sets, we
found a number of functional categories enriched in either one
of the 2 analyzed conditions, DMSO (Table 2, Table S1) and
LY294002 (Table S2, S3). The gene sets are organized in tables
based on their NES. UD gene sets were found to be associated
either with the control condition or the LY294002 treatment.
Some examples of the genes sets enriched in the LY294002
phenotype are: Cartilage, TGFB, Adipose, Wnt3, ECM, while
sets enriched in the DMSO phenotype include Sugar_ _bind,
Structure, Interleukin-related, Hormone, Blood and
Metabolism. The complete explanation of the C2 categories
names can be found in the supplementary tables S1 and S2.
Among the C2 gene sets, Adip_ _diff_ _cluster2, St_ _Wnt_ _Beta_ _
Catenin_ _Pathway, Vegf_ _Huvec_ _30min_ _up are associated
with the LY294002 treatment and Cholesterol_ _Biosynthesis,
IGF_ _vs_ _Pdgf_ _Up, Human_ _Tissue_ _Placenta are associated
with DMSO.
Figure 2. Functional categories identified by GO Biological Process associated with List #1 or with List #2. Functional categories
identified from GO biological process at level 6 were presented in the order of the adjusted p-value. The first two categories identified were mostly
associated with List #1 (genes both up-regulated in zone II and down-regulated by LY294002) and were represented by ‘‘steroid metabolic process’’
and ‘‘lipid biosynthetic process’’. The ‘‘Translation’’ category was also highly associated with List #1. In contrast, 11.19% of genes in List #2 (genes
both up-regulated in zone II and up-regulated by LY294002) were found in the ‘‘skeletal development’’ class. The percentage with term column
represents the percentage of the number of genes in each particular list (List #1 top red: List #2 bottom blue) related to the total number of genes
with annotations in both lists.
doi:10.1371/journal.pone.0008866.g002
PI3K in Chondrocytes
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The GSEA functional categories obtained from the previous
analysis were then intersected with genes differentially regulated
between DMSO and LY294002 treatments from the single gene
analysis array data. We intersected the gene sets associated with
the DMSO phenotype from the C2 and UD categories with genes
1.4-fold down-regulated in LY294002 treatment (Table S4, S5,
Column A). Similarly we intersected gene sets associated with the
LY294002 phenotype with genes 1.4-fold up-regulated in the
LY294002 treatment (Tables S6, S7, Column A).
Intersection of Genes in GSEA Categories, 1.4-Fold Down-
Regulated by LY294002 Treatment and 1.4-Fold Up-
Regulated in Zone II Compared to Zone I
Genes obtained from the intersection of the GSEA C2 or UD
categories with genes 1.4-fold down-regulated by LY294002 were
further intersected with genes up-regulated in the hypertrophic
zone (Zone II) (Table S4, S5, column B). From the final
intersection we selected specific genes for confirmation, based on
their identification in multiple C2 or UD categories and
information from the literature. F13a1 (coagulation factor XIII,
A1 subunit) was identified in both C2 and UD categories: in C2
Carries_ _Pulp_ _High_ _Up and Stossi_ _Er_ _Up and in UD
Blood and is 2-fold decreased in LY294002 compared to DMSO
(Table S4, S5). In addition, factor XIIIa has already been
implicated in chondrocyte hypertrophy [33], making it an
interesting candidate for further investigation. Phlda2 (pleckstrin
homology-like domain, family A, member 2) was identified in C2
Nakajima_ _Mcsmbp_ _Mast and Human_ _Tissue_ _Placenta
and is largely decreased in LY294002 (8-fold) compared to DMSO
(Table S4, S5). Phlda2 is also substantially increased in zone II
compared to I (,8-fold). There is no information on the role of
Phlda2 in bone growth and our study identified this gene as a
novel marker of chondrocyte hypertrophy. Phlda2 is known to be
involved in placental growth regulation and contains a PH domain
[34,35].
Intersection of Genes in GSEA Categories, 1.4-Fold Up-
Regulated by LY294002 Treatment and 1.4-Fold Down-
Regulated in Zone II Compared to I
Similar to the previous section, genes obtained from the
intersection of C2 or UD categories with genes 1.4-fold up-
regulated in LY294002 treatment were further intersected with
genes down-regulated in zone II of the growth plate compared to
zone I (Table S6, S7, column B). Nr4a1 and Adamts5 were selected
from the resulting gene list for further analyses. Nr4a1 (nuclear
receptor subfamily 4, group A, member 1) was 2.7-fold up-
regulated in LY294002 (Table S6, S7) and identified in
C2 AD12_ _Any_ _DN, AD12_ _24 hrs_ _DN and Vegf_ _Huvec_ _
30 min_ _UP and UD 2_ _DNAbind and Nucleus_ _2. It is also 2-
fold decreased in zone II compared to I. Nr4a1 (also known as
Nur77) is an orphan member of the nuclear receptor superfamily
and exerts opposing biological effects: proliferation, survival and
death after induction by extracellular stimuli. The mitogenic
activity of Nr4a1 requires DNA binding and translocation to the
nucleus [36]. It was suggested that Akt plays a positive a role in the
translocation of Nr4a1 from the nucleus to cytoplasm in
HEK293T cells [36] and that PI3K inhibition might be related
to Nur77 activation leading to apoptosis in HepG2 cells [37]. Our
data suggest that there is also regulation at transcriptional level. All
these findings make Nr4a1 a potential candidate as a target of the
PI3K/Akt pathway in growth plate. Adamts5 (a disintegrin-like and
metallopeptidase (reprolysin type) with thrombospondin type 1
motif, 5 (aggrecanase-2)) was found in UD Adipose, ECM and
Integrin_ _rel and is 4.7-fold down-regulated in zone II compared
to I. It is also 1.45-fold up-regulated in response to LY294002
treatment (Table S7). Adamts5 is mostly studied in connection
with osteoarthritis and in articular cartilage due to the observation
that Adamts5
2/2 mice are protected from cartilage degradation in
a model of osteoarthritis [38].
Pattern of Expression of Selected Genes Throughout the
Growth Plate
As shown in previous publications from our laboratory, well
known chondrocyte differentiation markers, such as Col10a1,
Mmp13, Ibsp and Sox family members, show the expected
expression pattern over the 3 zones in the growth plate
microdissection system [24] (James et al, PLoSONE, accepted
December 15
th, 2009.). The expression of the above selected genes
was analyzed throughout the growth plate. Adamts5 and Nr4a1 are
Table 2. User defined (UD) gene sets enriched in DMSO.
NAME
SIZE of
gene set ES NES
NOM
p-val
FDR
q-val
SUGAR_BIND 104 0.423 1.858 0.0004 0.014
MUSCLE 198 0.352 1.724 0.0004 0.030
STRUCTURE 151 0.351 1.653 0.0004 0.042
INTERLEUKINRELATED 175 0.343 1.650 ,0.0001 0.032
HORMONE 75 0.388 1.626 0.0048 0.032
GLUCONEOGEN 31 0.461 1.581 0.0206 0.040
TNF_RECEPTOR 69 0.368 1.508 0.0134 0.064
BLOOD 111 0.326 1.451 0.0117 0.089
CATALYTIC 245 0.274 1.378 0.0059 0.135
PROTEASE_1 269 0.264 1.345 0.0105 0.155
CHEMOKINE 31 0.383 1.335 0.0990 0.151
CYTOKINE 127 0.286 1.308 0.0522 0.166
METABOLISM 196 0.257 1.256 0.0597 0.220
PROTEASE_2 268 0.240 1.219 0.0615 0.261
HEPARIN BIND 37 0.325 1.163 0.2339 0.350
WNT_2 19 0.381 1.159 0.2661 0.336
RGS_RELATED 44 0.312 1.157 0.2326 0.319
NEG_APOPTOSIS 50 0.295 1.119 0.2777 0.382
HEPATOCYTE 19 0.346 1.040 0.3997 0.576
ERK_RELATED 40 0.284 1.039 0.3946 0.548
PHOSPHATASE 473 0.187 1.010 0.4053 0.614
CYTOPLASM 411 0.186 0.991 0.4841 0.644
POS_APOPTOSIS 79 0.234 0.984 0.4839 0.637
ACTIN_CYTOSKEL 38 0.265 0.960 0.5223 0.685
DUSP 20 0.311 0.946 0.5225 0.701
MEMBRANE 260 0.176 0.893 0.7874 0.824
ANGIOGEN 57 0.225 0.885 0.6628 0.813
LIVER_2 260 0.173 0.876 0.8444 0.804
OBL_OCLAST 16 0.246 0.710 0.8549 0.987
APOPTOSIS 39 0.187 0.680 0.9331 0.969
ES, enrichment score.
NES, normalized enrichment score.
NOM p-val, the uncorrected p-value.
FDR q-val, false discovery rate and multiple testing corrections (q-value).
doi:10.1371/journal.pone.0008866.t002
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While Phlda2 shows substantial increased expression in zone II
compared to the other two zones, F13a1 is also up-regulated in
zone III compared to zone II, maintaining high levels of
expression in terminal differentiated chondrocytes. Interestingly,
F13a1 shows a similar pattern of expression as genes with an
important role in terminal chondrocyte differentiation, such as
Col10a1, Ibsp and Mmp13 (Figure 1C, James et al, PLoSONE,
accepted December 15
th, 2009
Confirmation of Array Data by Real-Time PCR
A set of genes was chosen for the real-time validation of the
microarray data. Expression of F13a1 and Phlda2, chosen as target
genes of PI3K in hypertrophic chondrocyte differentiation, were
confirmed by real-time RT PCR. These genes showed a similar
trend and fold change compared to the microarray data: F13a1
(Figure 3E) and Phlda2 (Figure 3F) were 1.65- and 5-fold down-
regulated by LY294002. In contrast, Nr4a1 (Figure 3H) and
Adamts5 (Figure 3G) were 1.9- and 1.65-fold up-regulated
by LY294002, again validating the trends observed in our
microarrays.
Decreased Levels of Factor XIIIa in the Tibial Growth Plate
under PI3K Inhibition
The expression pattern of factor XIIIa has already been
analyzed in mammalian and avian growth plates [33,39,40] and
was shown to be increased in hypertrophic chondrocytes and areas
of mineralization. Factor XIIIa levels are also increased in
Figure 3. Real-time RT PCR confirmation of selected genes: F13a1, Nr4a1, Adamts5, Phlda2. Real-time PCR demonstrates that relative
transcript levels for F13a1 and Phlda2 were decreased in LY294002 treatment after 24 hours while Adamts5 and Nr4a1 transcripts were increased in
response to LY294002. Data were normalized to Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) mRNA levels. The results represent average
fold change between DMSO and LY294002 treatments from 4 independent trials (n=4). T-test -2 sample unequal variance was used and a *p-value ,
0.05 was considered significant.
doi:10.1371/journal.pone.0008866.g003
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articular cartilage [39]. For these reasons, we decided to follow up
on factor XIIIa as an interesting target of the PI3K pathway in
differentiated chondrocytes. To examine regulation of the
corresponding protein in the authentic three-dimensional context
of the intact growth plate, we cultured E15.5 mouse tibiae for 6
days in the presence of DMSO or 10 mM LY294002 and
processed them for immunohistochemistry (Figure 4A). The
F13a1 microarray expression pattern in the growth plate was
confirmed at the protein level, with increased levels in the
hypertrophic zone (Zone II) compared to the resting/proliferating
zone (Zone I) and the maintenance of this expression in the
mineralized area (Zone III), adding confidence to the results of the
microarray data analysis (Figure 1C). Protein levels of factor XIIIa
were markedly decreased in the LY294002-treated tibiae com-
pared to the DMSO control (Figure 4A). Factor XIIIa expression
levels were also quantified by western blotting in both primary cell
chondrocyte monolayer cultures and tibia organ cultures
(Figure 4B), showing that LY294002 treatment results in decreased
factor XIIIa protein levels. Interestingly, the factor XIIIa protein
size identified in our system was 37 kDa, which was also identified
as the cell and tissue specific form of factor XIIIa in chondrocyte
and osteoblast cultures, bone tissue and macrophages [41].
Increased Expression of Phlda2 in Zone II
The microarray expression pattern of Phlda2 was confirmed by
real-time PCR. Phlda2 was highly expressed in the prehyper-
trophic/hypertrophic growth plate zone (Zone II) (Figure 5A). The
expression pattern in the growth plate was also confirmed by
immunohistochemistry (Figure 5B, C).
Discussion
We have identified that the PI3K/Akt pathway plays a role in
hypertrophic chondrocyte differentiation in a previous publication
[11]. Here we present a model of target screening in hypertrophic
chondrocytes by comparing two different microarray systems, one
of primary chondrocytes treated with an inhibitor of the PI3K/Akt
pathway and the other one of microdissected growth plate
chondrocytes. By intersecting data obtained from these two
systems, we identified possible targets of the PI3K/Akt pathway
in hypertrophic chondrocyte differentiation.
One of the microarray systems used in this study was represented
by the comparison of gene expression in primary chondrocytes
isolated from E15.5 mouse long bones treated with the PI3K
inhibitor LY294002 or DMSO. Most of the genes differentially
regulated between the two treatments showed less than 1.4-fold
changes, suggesting that interfering with the PI3K regulation results
in small changes in gene expression, as also reported in previous
publications [3,7]. Considering these subtle changes in gene
expression, we performed additional microarray data analysis to
increase the probability of finding biologically significant targets. For
example, subtle changes in the expression of multiple genes involved
in the same biological process could still have biologically
meaningful consequences, even if changes appear minimal when
looking at individual genes. Therefore we implemented GSEA
analysis, which was created for data sets showing small changes in
gene expression. This method allows for analysis of gene sets
grouped in functional categories associated with LY294002
treatment or control phenotypes. These gene sets were then
intersected with genes 1.4-fold differentially regulated between
DMSO and LY294002 treatments. The resulting genes from this
intersection were further intersected with genes differentially
expressed between two zones of the microdissected growth plate:
zone I and II. The starting gene lists for these intersections were
represented by the reliable signal and not the statistical analysis and
reliable signal, as used before in other microarray data analyses from
our laboratory [21,22]. This approach was taken due to the
multistep process for data analyses in which t-test analyses might be
too stringent, eliminating biologically significant data.
We hypothesized that our dual approach of single gene analysis
and GSEA algorithm generates highly relevant biological targets
of the PI3K/Akt pathway in hypertrophic chondrocytes. The gene
set 1.4-fold down-regulated in LY294002 was intersected with
gene sets enriched in DMSO phenotype from the UD and C2 data
bases. The resulted gene sets were then intersected with genes up-
regulated in zone II compared to I (1.4-fold I , II). Using this
approach, we aimed to identify genes up-regulated by the PI3K/
Akt pathway under physiological conditions in hypertrophic
chondrocytes compared to proliferative/resting chondrocytes.
The same approach was also used to intersect genes down-
regulated by the PI3K/Akt pathway (1.4-fold up-regulated by
LY294002), enriched in the LY294002 phenotype in the GSEA
analysis and up-regulated in zone I compared to II (1.4-fold I .
II). However, the focus of our analysis was on the first intersection,
as the major effects of the PI3K/Akt pathway were identified in
Figure 4. Decreased factor XIIIa protein levels in the tibial
growth plate under PI3K inhibition. (A) E15.5 mouse tibiae
cultured for 6 days in the presence of DMSO or 10 mM LY294002 were
processed for immunohistochemistry. Protein levels of factor XIIIa were
decreased in the LY294002-treated growth plates compared to the
DMSO control, as shown by the red-brown stain (arrows). (B) Factor XIIIa
protein levels were also analyzed by western blotting in both primary
cell chondrocyte monolayer cultures after 24 hours and tibiae grown
for six days in organ culture, showing decreased factor XIIIa protein
levels under PI3K inhibition.
doi:10.1371/journal.pone.0008866.g004
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category, Phlda2 and F13a1 were also confirmed by real-time RT-
PCR. Factor XIIIa was found mostly intracellular in the
prehypertrophic-hypertrophic and mineralized areas, confirming
the microdissection microarray data. Factor XIIIa protein levels
decreased significantly upon PI3K inhibition, as noticed both in
the immunohistochemistry and western-blotting experiments. The
expression of factor XIIIa was also decreased in western blots from
monolayer and organ cultures, suggesting that our monolayer
microarray results are reflective of gene expression changes
occurring in the authentic three-dimensional context of the growth
plate. The size of the factor XIIIa protein identified in our cultures
was 37 kDa, which has been shown to be specific for cartilage/
bone tissues and macrophages and is an intracellular form of factor
XIIIa [41]. The factor XIIIa was also identified as having a role in
osteoarthritis [39], being associated with hypertrophic-like cells. In
future experiments it would be of value to test the effects of the
PI3K/Akt inhibition on the factor XIIIa in osteoarthritis models.
Considering the toxic effects of the LY294002 and the lack of
other non-toxic specific PI3K inhibitors for the moment, the
system in which this experiment could be performed is an organ
culture model of cartilage degradation.
In addition, we identified Phlda2 as a novel marker
for hypertrophic chondrocytes, showing high expression in
Figure 5. Increased expression of Phlda2 in the hypertrophic zone. (A) RNA was isolated from the 3 growth plate zones. Real-time PCR
analyses showed increased expression of Phlda2 in Zone II compared to Zone I and III. The lowest levels of expression were observed in zone III (13.6
fold change compared to zone II). The presented results are relative to Gapdh endogenous control; n=3, *p,0.05. (B) Expression pattern of Phlda2
within the growth plate after 6 days of culture in the presence of DMSO. Immunohistochemistry analysis showed increased expression of Phlda2 in
prehypertrophic/hypertrophic chondrocytes (Zone II) (red-brown stain). (C) The inset shows a higher magnification of Zone II.
doi:10.1371/journal.pone.0008866.g005
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immunohistochemistry.
We observed that a high number of genes are both up-
regulated in zone II compared to zone I (therefore associated
with a chondrocyte hypertrophic phenotype) and down-regulat-
ed by LY294002 (371 genes). A large number of genes were also
up-regulated by LY294002 and in zone II (297 genes); therefore
we cannot conclude that the PI3K pathway has a general
stimulatory effect on expression of hypertrophic genes. Interest-
ingly, the genes down-regulated by LY294002, in contrast to the
ones up-regulated by LY294002, were identified by GO
Biological Process analysis as part of a few lipid metabolic
groups. It is known that hypertrophic chondrocytes are highly
metabolically active cells [42,43]. In addition, it was suggested
before that cholesterol signaling stimulates chondrocyte hyper-
trophy [23]. Therefore, even if some genes up-regulated in the
hypertrophic zone are also up-regulated by LY294002, they do
not seem to be associated with the changes in lipid metabolism
during hypertrophy.
In this study we propose a model for identification of PI3K/Akt
signaling pathway targets in the hypertrophic stage of chondrocyte
differentiation. This model could also be expanded to other
pathways and organ systems. Due to the combined microarray
approach, the possibility of identifying biologically significant
targets is high, as demonstrated by our identification of F13a1 as a
target of the PI3K/Akt pathway in hypertrophic chondrocytes and
Phlda2 as a novel hypertrophic marker.
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